Cancer vaccines have been developed largely as therapeutic approaches targeting specific tumor antigens while sparing the deleterious and generalized immune-suppressive effects of radiation and chemotherapy.
"First Generation" cancer vaccines (such as Provenge) are autologous preparations and patient-specific. This approach has shown some success, but like anti-tumor monoclonal antibody products, it is limited by tumor mutations that render the vaccine less effective.
"Second Generation" anti-cancer vaccines and immunotherapies aim to correct this deficiency by utilizing universal or heterologous antigens. These vaccines and therapies often require an in vivo rather than an in vitro approach to generate the anti-tumor immune response. This approach aims to utilize the patient's immune system to generate an anti-tumor immune response and destroy the tumor. Through imparting exogenous and activating endogenous anti-tumor mechanisms within the patient to overcome tumor tolerance and generate a robust, sustainable and effective anti-tumor immune response, this response may be able to withstand tumor mutations and overcome tumor mechanisms geared towards the inhibition of an effective anti-tumor response in the patient.
This symposium will highlight current approaches in cancer immunotherapy and immunomodulation, and emerging cancer vaccines.
Reception to follow.
This event will also be broadcast as a webinar.
Please note: Transmission of presentations via the webinar is subject to individual consent by the speakers. Therefore, we cannot guarantee that every speaker’s presentation will be broadcast in full via the webinar. To access all speakers’ presentations in full, we invite you to attend the live event in New York City where possible.
|Student / Postdoc / Fellow Member
|Student / Postdoc / Fellow Nonmember
This meeting is part of our Translational Medicine Initiative, sponsored by the Josiah Macy Jr. Foundation.